CS
OLMA icon

Candriam SCA’s Olema Pharmaceuticals OLMA Stock Holding History

Candriam SCA’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3M Buy
759,513
+80,029
+12% +$1.78M 0.06% 261
2025
Q4 		$17M Sell
679,484
-570,243
-46% -$10.1M 0.08% 207
2025
Q3 		$12.2M Buy
1,249,727
+399,273
+47% +$2.4M 0.06% 248
2025
Q2 		$3.62M Sell
850,454
-63
-0% -$281 0.02% 406
2025
Q1 		$3.2M Sell
850,517
-701,045
-45% -$3.53M 0.02% 414
2024
Q4 		$9.05M Buy
1,551,562
+44,798
+3% +$447K 0.05% 277
2024
Q3 		$18M Buy
1,506,764
+448,091
+42% +$5.73M 0.1% 196
2024
Q2 		$11.5M Buy
1,058,673
+705,655
+200% +$7.65M 0.07% 238
2024
Q1 		$4M Buy
353,018
+138,010
+64% +$1.78M 0.03% 381
2023
Q4 		$3.02M Buy
+215,008
New +$2.89M 0.02% 418
2022
Q1 		– Sell
-332,572
Closed -$3.11M – 838
2021
Q4 		$3.11M Sell
332,572
-10,000
-3% -$207K 0.02% 458
2021
Q3 		$9.44M Sell
342,572
-7,000
-2% -$189K 0.06% 285
2021
Q2 		$9.78M Buy
349,572
+349,559
+2,688,915% +$9.95M 0.07% 289
2021
Q1 		$0 Buy
+13
New +$557 ﹤0.01% 817

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Candriam SCA's OLMA Position: Q1 2026 in Review

Candriam SCA increased its Olema Pharmaceuticals (OLMA) stake by 12% in Q1 2026, buying an estimated $1.78M and bringing the position to 759,513 shares worth $11.3M. The position accounts for 0.06% of the portfolio, ranked #261.

Candriam SCA first reported a position in OLMA in Q1 2021 and has held it in 14 quarters since. The position peaked at $18M in Q3 2024. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Candriam SCA held 759,513 shares of Olema Pharmaceuticals worth $11.3M as of Q1 2026.
  • Candriam SCA bought 80,029 Olema Pharmaceuticals shares in Q1 2026, an estimated $1.78M.
  • Olema Pharmaceuticals made up 0.06% of Candriam SCA's portfolio in Q1 2026, its #261 holding.
  • Candriam SCA first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • Candriam SCA's Olema Pharmaceuticals position peaked at $18M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.